KBIO LABS (A038530) 주식 개요케이비오랩스는 바이오 유통 사업을 영위하고 있습니다. 자세히 보기A038530 펀더멘털 분석스노우플레이크 점수가치 평가4/6미래 성장0/6과거 실적0/6재무 건전성6/6배당0/6강점공정 가치 추정치보다 낮은 98.4% 에서 거래지난 5년 동안 수입이 매년 21.7% 증가했습니다.위험 분석의미 있는 시가총액이 없습니다(₩28B)모든 위험 점검 보기A038530 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₩Current Price₩1.21k53.5% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-17b87b2016201920222025202620282031Revenue ₩87.3bEarnings ₩5.7bAdvancedSet Fair ValueView all narrativesKBIO LABS Inc. 경쟁사Kyungin ElectronicsSymbol: KOSE:A009140Market cap: ₩35.2bSAMJINSymbol: KOSDAQ:A032750Market cap: ₩29.0bInter-MSymbol: KOSDAQ:A017250Market cap: ₩22.7bNamsungSymbol: KOSE:A004270Market cap: ₩22.4b가격 이력 및 성과KBIO LABS 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가₩1,207.0052주 최고가₩2,750.0052주 최저가₩1,125.00베타0.921개월 변동-22.13%3개월 변동-39.95%1년 변동-13.17%3년 변동-51.72%5년 변동-81.07%IPO 이후 변동-99.74%최근 뉴스 및 업데이트공시 • Feb 26KBIO COMPANY Inc., Annual General Meeting, Mar 31, 2026KBIO COMPANY Inc., Annual General Meeting, Mar 31, 2026, at 08:30 Tokyo Standard Time. Location: conference room, 375, sowol-ro, yongsan-gu, seoul South Korea분석 기사 • Feb 04KBIO COMPANY Inc. (KOSDAQ:038530) Held Back By Insufficient Growth Even After Shares Climb 56%KBIO COMPANY Inc. ( KOSDAQ:038530 ) shareholders would be excited to see that the share price has had a great month...New Risk • Feb 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩43.3b market cap, or US$29.7m).분석 기사 • Nov 21Not Many Are Piling Into KBIO COMPANY Inc. (KOSDAQ:038530) Just YetWith a price-to-sales (or "P/S") ratio of 0.3x KBIO COMPANY Inc. ( KOSDAQ:038530 ) may be sending bullish signals at...New Risk • Aug 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). High level of non-cash earnings (28% accrual ratio). Minor Risk Market cap is less than US$100m (₩31.8b market cap, or US$22.9m).Buy Or Sell Opportunity • Jun 30Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 9.8% to ₩257. The fair value is estimated to be ₩214, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 43% over the last 3 years. Earnings per share has grown by 49%.더 많은 업데이트 보기Recent updates공시 • Feb 26KBIO COMPANY Inc., Annual General Meeting, Mar 31, 2026KBIO COMPANY Inc., Annual General Meeting, Mar 31, 2026, at 08:30 Tokyo Standard Time. Location: conference room, 375, sowol-ro, yongsan-gu, seoul South Korea분석 기사 • Feb 04KBIO COMPANY Inc. (KOSDAQ:038530) Held Back By Insufficient Growth Even After Shares Climb 56%KBIO COMPANY Inc. ( KOSDAQ:038530 ) shareholders would be excited to see that the share price has had a great month...New Risk • Feb 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩43.3b market cap, or US$29.7m).분석 기사 • Nov 21Not Many Are Piling Into KBIO COMPANY Inc. (KOSDAQ:038530) Just YetWith a price-to-sales (or "P/S") ratio of 0.3x KBIO COMPANY Inc. ( KOSDAQ:038530 ) may be sending bullish signals at...New Risk • Aug 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). High level of non-cash earnings (28% accrual ratio). Minor Risk Market cap is less than US$100m (₩31.8b market cap, or US$22.9m).Buy Or Sell Opportunity • Jun 30Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 9.8% to ₩257. The fair value is estimated to be ₩214, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 43% over the last 3 years. Earnings per share has grown by 49%.분석 기사 • Apr 08Here's Why We're Not At All Concerned With KBIO's (KOSDAQ:038530) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Reported Earnings • Mar 22Full year 2024 earnings released: ₩59.00 loss per share (vs ₩116 loss in FY 2023)Full year 2024 results: ₩59.00 loss per share (improved from ₩116 loss in FY 2023). Revenue: ₩76.5b (up 180% from FY 2023). Net loss: ₩6.79b (loss narrowed 43% from FY 2023). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.공시 • Mar 12KBIO COMPANY Inc., Annual General Meeting, Mar 26, 2025KBIO COMPANY Inc., Annual General Meeting, Mar 26, 2025, at 08:30 Tokyo Standard Time. Location: conference room, 375, sowal-ro, yongsan-gu, seoul South Korea분석 기사 • Jan 08Market Might Still Lack Some Conviction On KBIO COMPANY Inc. (KOSDAQ:038530) Even After 38% Share Price BoostKBIO COMPANY Inc. ( KOSDAQ:038530 ) shareholders would be excited to see that the share price has had a great month...New Risk • Jan 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₩33.8b market cap, or US$23.2m).Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improves as stock rises 33%After last week's 33% share price gain to ₩293, the stock trades at a trailing P/E ratio of 21.2x. Average trailing P/E is 16x in the Semiconductor industry in South Korea. Total loss to shareholders of 77% over the past three years.New Risk • Dec 07New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). High level of non-cash earnings (28% accrual ratio). Minor Risk Market cap is less than US$100m (₩27.0b market cap, or US$19.0m).분석 기사 • Nov 22We Think KBIO's (KOSDAQ:038530) Robust Earnings Are ConservativeKBIO COMPANY Inc. ( KOSDAQ:038530 ) recently posted some strong earnings, and the market responded positively. We did...New Risk • Aug 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 7.1% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩42.6b market cap, or US$31.5m).분석 기사 • Jul 16KBIO (KOSDAQ:038530) Is In A Strong Position To Grow Its BusinessJust because a business does not make any money, does not mean that the stock will go down. For example, although...분석 기사 • Mar 27We're Not Worried About KBIO's (KOSDAQ:038530) Cash BurnThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...New Risk • Nov 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 24% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (₩34.9b market cap, or US$26.9m).New Risk • Aug 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 24% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (₩43.1b market cap, or US$32.7m).Board Change • Jul 21Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Jun 15Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Apr 10Gold Pacific Co., Ltd. announced that it has received KRW 8.001 billion in funding from Elim CorporationOn April 9, 2021, Gold Pacific Co., Ltd. (KOSDAQ:A038530) closed the transaction.Is New 90 Day High Low • Mar 03New 90-day low: ₩1,335The company is down 18% from its price of ₩1,630 on 03 December 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Semiconductor industry, which is up 25% over the same period.공시 • Jan 23Gold Pacific Co., Ltd. announced that it has received KRW 10 billion in fundingOn January 22, 2021, Gold Pacific Co., Ltd. (KOSDAQ:A038530) closed the transaction.. The conversion of bonds will start on January 22, 2022 and end on December 22, 2023. The maturity date of bonds has changed to January 22, 2024.공시 • Jan 20Gold Pacific Co., Ltd. announced that it expects to receive KRW 10 billion in fundingGold Pacific Co., Ltd. (KOSDAQ:A038530) announced a private placement of Series 25 Non-Guaranteed private equity bond with underwriting rights for gross proceeds of KRW 10,000,000,000 on January 19, 2021. The transaction will include participation from Macrona Fund for 7,000,000,000 bonds and individual investor Kim Hooseong for 3,000,000,000. The bonds bear a fixed coupon rate of 1% and interest rate to maturity of 1%. The bonds will mature on February 2, 2024. The bonds are 100% convertible at a fixed conversion price of KRW 1,571 per share into 6,365,372 shares from February 2, 2022 to January 2, 2024. The subscription date of the bonds is January 21, 2021 and the payment date if February 2, 2021.Is New 90 Day High Low • Jan 11New 90-day low: ₩1,355The company is down 40% from its price of ₩2,265 on 13 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Semiconductor industry, which is up 43% over the same period.공시 • Oct 13Gold Pacific Co., Ltd. announced that it expects to receive KRW 10.000084 billion in fundingGold Pacific Co., Ltd. (KOSDAQ:A038530) announced private placement of 6,046,000 shares at a price of KRW 1,654 per share for gross proceeds of KRW 10,000,084,000 with Kaid Fund on October 12, 2020. The expected payment date is April 09, 2021. The shares are subject to lock up for 1 year. The transaction is approved by the board of directors of the company.Is New 90 Day High Low • Oct 08New 90-day high: ₩1,985The company is up 32% from its price of ₩1,505 on 10 July 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Semiconductor industry, which is up 4.0% over the same period.공시 • Sep 22Gold Pacific Co., Ltd. announced that it has received KRW 10 billion in funding from Chorokbaem Media Co., Ltd., Philosys Healthcare Co., LtdOn September 17, 2020, Gold Pacific Co., Ltd. (KOSDAQ:A038530) closed the transaction.공시 • Sep 09Gold Pacific Co., Ltd. announced that it expects to receive KRW 10 billion in funding from Chorokbaem Media Co., Ltd., Philosys Healthcare Co., LtdGold Pacific Co., Ltd. (KOSDAQ:A038530) announced that it will receive KRW 10,000,000,000 in a round of funding on September 8, 2020. The company will issue series 24 unregistered non-guaranteed coupon private convertible bonds in the transaction. The transaction will include participation from Chorokbaem Media Co., Ltd. (KOSDAQ:A047820) for KRW 5,000,000,000 and Philosys Healthcare Co., Ltd (KOSDAQ:A057880) for KRW 5,000,000,000. The bonds bear a fixed coupon rate of 1% and yield to maturity rate of 1%. The bonds will mature on September 17, 2023. The bonds are fully convertible at fixed conversion price of KRW 1,419 per share into 7,047,216 common shares from September 17, 2021 to August 17, 2023. The subscription date of the bonds is September 10, 2020 and the payment date of the bonds is September 17, 2020. The transaction was approved by the board of directors of the company.주주 수익률A038530KR Consumer DurablesKR 시장7D-4.3%-1.6%4.6%1Y-13.2%119.6%186.6%전체 주주 수익률 보기수익률 대 산업: A038530은 지난 1년 동안 119.6%의 수익을 기록한 KR Consumer Durables 산업보다 저조한 성과를 냈습니다.수익률 대 시장: A038530은 지난 1년 동안 186.6%를 기록한 KR 시장보다 저조한 성과를 냈습니다.주가 변동성Is A038530's price volatile compared to industry and market?A038530 volatilityA038530 Average Weekly Movement10.6%Consumer Durables Industry Average Movement6.6%Market Average Movement9.4%10% most volatile stocks in KR Market16.6%10% least volatile stocks in KR Market4.9%안정적인 주가: A038530는 지난 3개월 동안 KR 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: A038530의 주간 변동성(11%)은 지난 1년 동안 안정적이었습니다.회사 소개설립직원 수CEO웹사이트199736JungYoung Chowww.kbiocompany.com케이비오랩스는 바이오 유통 사업을 영위하고 있습니다. 생명과학 관련 장비와 시약을 병원과 대학에 유통하고 있습니다. 또한 DVR, 영상보안 솔루션 등 영상보안 장비도 개발합니다.더 보기KBIO LABS Inc. 기초 지표 요약KBIO LABS의 순이익과 매출은 시가총액과 어떻게 비교됩니까?A038530 기초 통계시가총액₩27.88b순이익 (TTM)-₩3.20b매출 (TTM)₩87.31b0.3x주가매출비율(P/S)-8.7x주가수익비율(P/E)A038530는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표A038530 손익계산서 (TTM)매출₩87.31b매출원가₩74.79b총이익₩12.52b기타 비용₩15.72b순이익-₩3.20b최근 보고된 실적Dec 31, 2025다음 실적 발표일해당 없음주당순이익(EPS)-138.51총이익률14.34%순이익률-3.66%부채/자본 비율0%A038530의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/24 18:30종가2026/05/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스KBIO LABS Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Feb 26KBIO COMPANY Inc., Annual General Meeting, Mar 31, 2026KBIO COMPANY Inc., Annual General Meeting, Mar 31, 2026, at 08:30 Tokyo Standard Time. Location: conference room, 375, sowol-ro, yongsan-gu, seoul South Korea
분석 기사 • Feb 04KBIO COMPANY Inc. (KOSDAQ:038530) Held Back By Insufficient Growth Even After Shares Climb 56%KBIO COMPANY Inc. ( KOSDAQ:038530 ) shareholders would be excited to see that the share price has had a great month...
New Risk • Feb 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩43.3b market cap, or US$29.7m).
분석 기사 • Nov 21Not Many Are Piling Into KBIO COMPANY Inc. (KOSDAQ:038530) Just YetWith a price-to-sales (or "P/S") ratio of 0.3x KBIO COMPANY Inc. ( KOSDAQ:038530 ) may be sending bullish signals at...
New Risk • Aug 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). High level of non-cash earnings (28% accrual ratio). Minor Risk Market cap is less than US$100m (₩31.8b market cap, or US$22.9m).
Buy Or Sell Opportunity • Jun 30Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 9.8% to ₩257. The fair value is estimated to be ₩214, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 43% over the last 3 years. Earnings per share has grown by 49%.
공시 • Feb 26KBIO COMPANY Inc., Annual General Meeting, Mar 31, 2026KBIO COMPANY Inc., Annual General Meeting, Mar 31, 2026, at 08:30 Tokyo Standard Time. Location: conference room, 375, sowol-ro, yongsan-gu, seoul South Korea
분석 기사 • Feb 04KBIO COMPANY Inc. (KOSDAQ:038530) Held Back By Insufficient Growth Even After Shares Climb 56%KBIO COMPANY Inc. ( KOSDAQ:038530 ) shareholders would be excited to see that the share price has had a great month...
New Risk • Feb 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩43.3b market cap, or US$29.7m).
분석 기사 • Nov 21Not Many Are Piling Into KBIO COMPANY Inc. (KOSDAQ:038530) Just YetWith a price-to-sales (or "P/S") ratio of 0.3x KBIO COMPANY Inc. ( KOSDAQ:038530 ) may be sending bullish signals at...
New Risk • Aug 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). High level of non-cash earnings (28% accrual ratio). Minor Risk Market cap is less than US$100m (₩31.8b market cap, or US$22.9m).
Buy Or Sell Opportunity • Jun 30Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 9.8% to ₩257. The fair value is estimated to be ₩214, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 43% over the last 3 years. Earnings per share has grown by 49%.
분석 기사 • Apr 08Here's Why We're Not At All Concerned With KBIO's (KOSDAQ:038530) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Reported Earnings • Mar 22Full year 2024 earnings released: ₩59.00 loss per share (vs ₩116 loss in FY 2023)Full year 2024 results: ₩59.00 loss per share (improved from ₩116 loss in FY 2023). Revenue: ₩76.5b (up 180% from FY 2023). Net loss: ₩6.79b (loss narrowed 43% from FY 2023). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.
공시 • Mar 12KBIO COMPANY Inc., Annual General Meeting, Mar 26, 2025KBIO COMPANY Inc., Annual General Meeting, Mar 26, 2025, at 08:30 Tokyo Standard Time. Location: conference room, 375, sowal-ro, yongsan-gu, seoul South Korea
분석 기사 • Jan 08Market Might Still Lack Some Conviction On KBIO COMPANY Inc. (KOSDAQ:038530) Even After 38% Share Price BoostKBIO COMPANY Inc. ( KOSDAQ:038530 ) shareholders would be excited to see that the share price has had a great month...
New Risk • Jan 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₩33.8b market cap, or US$23.2m).
Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improves as stock rises 33%After last week's 33% share price gain to ₩293, the stock trades at a trailing P/E ratio of 21.2x. Average trailing P/E is 16x in the Semiconductor industry in South Korea. Total loss to shareholders of 77% over the past three years.
New Risk • Dec 07New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). High level of non-cash earnings (28% accrual ratio). Minor Risk Market cap is less than US$100m (₩27.0b market cap, or US$19.0m).
분석 기사 • Nov 22We Think KBIO's (KOSDAQ:038530) Robust Earnings Are ConservativeKBIO COMPANY Inc. ( KOSDAQ:038530 ) recently posted some strong earnings, and the market responded positively. We did...
New Risk • Aug 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 7.1% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩42.6b market cap, or US$31.5m).
분석 기사 • Jul 16KBIO (KOSDAQ:038530) Is In A Strong Position To Grow Its BusinessJust because a business does not make any money, does not mean that the stock will go down. For example, although...
분석 기사 • Mar 27We're Not Worried About KBIO's (KOSDAQ:038530) Cash BurnThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
New Risk • Nov 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 24% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (₩34.9b market cap, or US$26.9m).
New Risk • Aug 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 24% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (₩43.1b market cap, or US$32.7m).
Board Change • Jul 21Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Jun 15Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Apr 10Gold Pacific Co., Ltd. announced that it has received KRW 8.001 billion in funding from Elim CorporationOn April 9, 2021, Gold Pacific Co., Ltd. (KOSDAQ:A038530) closed the transaction.
Is New 90 Day High Low • Mar 03New 90-day low: ₩1,335The company is down 18% from its price of ₩1,630 on 03 December 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Semiconductor industry, which is up 25% over the same period.
공시 • Jan 23Gold Pacific Co., Ltd. announced that it has received KRW 10 billion in fundingOn January 22, 2021, Gold Pacific Co., Ltd. (KOSDAQ:A038530) closed the transaction.. The conversion of bonds will start on January 22, 2022 and end on December 22, 2023. The maturity date of bonds has changed to January 22, 2024.
공시 • Jan 20Gold Pacific Co., Ltd. announced that it expects to receive KRW 10 billion in fundingGold Pacific Co., Ltd. (KOSDAQ:A038530) announced a private placement of Series 25 Non-Guaranteed private equity bond with underwriting rights for gross proceeds of KRW 10,000,000,000 on January 19, 2021. The transaction will include participation from Macrona Fund for 7,000,000,000 bonds and individual investor Kim Hooseong for 3,000,000,000. The bonds bear a fixed coupon rate of 1% and interest rate to maturity of 1%. The bonds will mature on February 2, 2024. The bonds are 100% convertible at a fixed conversion price of KRW 1,571 per share into 6,365,372 shares from February 2, 2022 to January 2, 2024. The subscription date of the bonds is January 21, 2021 and the payment date if February 2, 2021.
Is New 90 Day High Low • Jan 11New 90-day low: ₩1,355The company is down 40% from its price of ₩2,265 on 13 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Semiconductor industry, which is up 43% over the same period.
공시 • Oct 13Gold Pacific Co., Ltd. announced that it expects to receive KRW 10.000084 billion in fundingGold Pacific Co., Ltd. (KOSDAQ:A038530) announced private placement of 6,046,000 shares at a price of KRW 1,654 per share for gross proceeds of KRW 10,000,084,000 with Kaid Fund on October 12, 2020. The expected payment date is April 09, 2021. The shares are subject to lock up for 1 year. The transaction is approved by the board of directors of the company.
Is New 90 Day High Low • Oct 08New 90-day high: ₩1,985The company is up 32% from its price of ₩1,505 on 10 July 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Semiconductor industry, which is up 4.0% over the same period.
공시 • Sep 22Gold Pacific Co., Ltd. announced that it has received KRW 10 billion in funding from Chorokbaem Media Co., Ltd., Philosys Healthcare Co., LtdOn September 17, 2020, Gold Pacific Co., Ltd. (KOSDAQ:A038530) closed the transaction.
공시 • Sep 09Gold Pacific Co., Ltd. announced that it expects to receive KRW 10 billion in funding from Chorokbaem Media Co., Ltd., Philosys Healthcare Co., LtdGold Pacific Co., Ltd. (KOSDAQ:A038530) announced that it will receive KRW 10,000,000,000 in a round of funding on September 8, 2020. The company will issue series 24 unregistered non-guaranteed coupon private convertible bonds in the transaction. The transaction will include participation from Chorokbaem Media Co., Ltd. (KOSDAQ:A047820) for KRW 5,000,000,000 and Philosys Healthcare Co., Ltd (KOSDAQ:A057880) for KRW 5,000,000,000. The bonds bear a fixed coupon rate of 1% and yield to maturity rate of 1%. The bonds will mature on September 17, 2023. The bonds are fully convertible at fixed conversion price of KRW 1,419 per share into 7,047,216 common shares from September 17, 2021 to August 17, 2023. The subscription date of the bonds is September 10, 2020 and the payment date of the bonds is September 17, 2020. The transaction was approved by the board of directors of the company.
